Monday, September 8, 2025

Latest

Tilray: Canaccord Cuts Price Target To $9.00

On January 10th, Tilray Inc (TSX: TLRY) reported their fiscal second-quarter financial results, the company saw net revenues of $155.15 million, an increase of 20% year over year. The company reported an adjusted EBITDA of $13.8 million and a net income of $95 million, driven by a reassessment of fair value derivative liabilities.

The companies revenues are made up of 38% cannabis, 44% distribution, 9% beverages, and 9% wellness. Once again showcasing that Cannabis revenue is not the main driver of revenue for Tilray.

For the cannabis sector, gross margins were 23%, or $13.52 million, while adjusted gross margins, which remove inventory impairment, came in at 43% or $25.52 million.

Tilray saw a number of analysts cut their 12-month price targets on the firm from US$12.38 to US$9.79, which now represents a 35% upside to the current stock price. Tilray has 20 analysts covering the stock with 1 analyst having a strong buy rating, 2 have buys, 14 have hold ratings and 3 have sell ratings. Cowen and Company has the street high price target of US$23 while GLJ Research currently has a US$0.82 price target.

Canaccord Genuity slashed their 12-month price target from US$12 to US$9 and reiterated their hold rating on Tilray after the results, saying that sustained market saturation continues to lead to declining branded sales.

For the results, Canaccord expected Tilray to report $162 million in revenues with an adjusted gross margin of $45.36 million, which Tilray did not meet. Tilray saw Canadian adult-use revenue drop 29% while price compression continues to be the biggest problem for Tilray.

Canaccord calls Tilray’s Canadian market share decline from 16% to 12.8% well behind its goal of 30% market share, a red flag for the sector as a whole as most of the LPs are still struggling to ‘gain critical mass.”

For its other segments, Tilray holds a 20% market share in Germany which Canaccord says, “looks to be on the verge of potentially formalizing adult-use regulations.” While beverage and wellness revenue saw a 9.5% sequential decrease due to what Canaccord calls a slowing CBD market.

Below you can see Canaccord’s updated fiscal full-year 2022 and 2023 estimates below.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Avino Q2 Earnings: Steady As She Goes

MEG Energy: Cenovus Comes In With $7.9 BILLION Offer

Orla Mining Q2 Earnings: Musselwhite Changes Everything

Recommended

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

Related News

Bombardier: TD, Veritas Raise Price Target, BMO Cuts

Last week, Bombardier (TSX: BBD.b) reported second quarter 2020 financials, reporting $2.7 billion in revenues...

Monday, August 10, 2020, 02:12:00 PM

Canopy Growth: Analysts Anticipate Q1 Revenues Of $149 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal...

Tuesday, August 3, 2021, 03:28:00 PM

Lundin Mining Sees BMO Maintain Price Target Following Q3 Earnings

Yesterday Lundin Mining (TSX: LUN) reported their third quarter earnings. Third-quarter cash flows were +$272.2...

Thursday, October 29, 2020, 03:29:00 PM

Canaccord Lowers Else Nutrition Estimates After Disappointing Quarter

This past week, Else Nutrition (CSE: BABY) reported their second quarter financial results. The company...

Friday, September 3, 2021, 11:11:00 AM

Organigram: Mixed Commentary From Analysts Following Q1 2021 Results

Organigram Holdings (TSX: OGI) (NASDAQ: OGI) yesterday morning reported its first-quarter 2021 financial results for...

Wednesday, January 13, 2021, 11:55:00 AM